Seretra (Seratrodast)

What is Seratrodast?

Seratrodast is a selective thromboxane A₂ receptor antagonist used primarily for the management of allergic conditions, including bronchial asthma and allergic rhinitis. It works by blocking the effects of thromboxane A₂—a potent mediator of bronchoconstriction and inflammation—thereby helping to reduce airway narrowing and inflammatory responses.

Reference: U.S. Food and Drug Administration (FDA); WHO; PubMed (e.g., Ishiguro et al., 2000)

What are the other popular names for Seratrodast?

Seratrodast is known by its generic name “seratrodast” and is marketed under various brand names depending on the region. In some markets, it may be available under brand names such as Seratol or Seratast, though naming conventions can vary internationally.

Reference: U.S. FDA; MedlinePlus; WHO

What is the drug classification of Seratrodast?

Seratrodast is classified as an antiallergic agent and, more specifically, as a selective thromboxane A₂ receptor antagonist. It belongs to a group of medications used to manage allergic inflammation and bronchoconstriction in respiratory conditions.

Reference: U.S. FDA; World Health Organization (WHO) guidelines on allergic diseases

What is the mode of action of Seratrodast?

Seratrodast works by selectively blocking thromboxane A₂ (TXA₂) receptors on airway smooth muscle and inflammatory cells. By inhibiting the action of TXA₂, it reduces bronchoconstriction and limits the release of inflammatory mediators. This action helps improve airflow and reduces symptoms associated with allergic asthma and allergic rhinitis.

Reference: PubMed – Studies on thromboxane receptor antagonists in asthma (e.g., Ishiguro et al., 2000); WHO

What are the primary uses of Seratrodast?

Seratrodast is used primarily in the management of:

• Allergic Bronchial Asthma: To reduce bronchospasm and inflammation.
• Allergic Rhinitis: To alleviate nasal symptoms related to allergies.
• Other Allergic Conditions: Where thromboxane-mediated inflammation plays a role.

Reference: U.S. FDA; WHO; ClinicalTrials.gov

What is the recommended dosage and administration for Seratrodast?

• Dosage: In adults, the typical dosage is 100 mg per day, often given as 50 mg twice daily.
• Administration:
  • Seratrodast tablets should be taken orally with water.
  • It is best taken with food to minimize gastrointestinal discomfort.
  • Dosage adjustments may be required based on clinical response and tolerability.

Reference: PubMed (e.g., clinical study by Ishiguro et al., 2000); U.S. FDA

What prescribing information is important for Seratrodast?

• Indications:
  • Indicated for the treatment of allergic bronchial asthma and allergic rhinitis, particularly in patients who do not achieve adequate symptom control with standard therapy.
• Contraindications:
  • Contraindicated in patients with known hypersensitivity to seratrodast or any of its components.
  • Use with caution in patients with severe hepatic impairment.
• Monitoring:
  • Liver function tests should be monitored periodically in patients with pre-existing hepatic conditions.
  • Symptom improvement should be assessed regularly.

Reference: U.S. FDA; WHO; ClinicalTrials.gov

What safety information, side effects, warnings, and cautions are associated with Seratrodast?

• Common Side Effects:
  • Headache, gastrointestinal discomfort (nausea, dyspepsia), and mild skin reactions (rash).
• Serious Side Effects (Rare):
  • Dizziness or hypotension may occur.
  • In rare cases, allergic reactions can be severe.
• Warnings & Cautions:
  • Hepatic Caution: Monitor liver enzymes in patients with liver dysfunction.
  • Pregnancy and Lactation: Limited data exist; use only if the potential benefit justifies the risk. Effective contraception is advised in women of childbearing potential.
  • Drug Interactions: Caution is warranted when seratrodast is used concurrently with other agents that may affect its metabolism (e.g., CYP inhibitors).

Reference: U.S. FDA; PubMed; WHO

What drug interactions should be considered with Seratrodast?

• CYP Enzyme Modulators:
  • Concomitant use with drugs that inhibit CYP450 enzymes (e.g., certain antifungals or macrolide antibiotics) may increase seratrodast plasma levels.
• Other Anti-Allergic Medications:
  • Concurrent use with other antiallergic or anti-inflammatory agents may require dose adjustments or increased monitoring.
• Hepatotoxic Drugs:
  • Use with other medications known to impact liver function should be approached with caution.

Reference: U.S. FDA; Clinical Pharmacology Reviews on PubMed

Where can I find additional clinical evidence and detailed information about Seratrodast?

For further details on clinical studies, dosing guidelines, and safety monitoring:

• U.S. Food and Drug Administration (FDA) Website: FDA.gov
• ClinicalTrials.gov: Search for seratrodast studies
• PubMed: For peer‑reviewed research articles on seratrodast’s efficacy and safety (e.g., Ishiguro et al., 2000)
• World Health Organization (WHO): Guidelines on allergic diseases and treatment protocols

Reference: U.S. FDA; PubMed; WHO

Final Thoughts

Seratrodast is a valuable selective thromboxane A₂ receptor antagonist used to manage allergic bronchial asthma and allergic rhinitis by reducing bronchoconstriction and inflammation. Its ability to improve airflow and alleviate allergic symptoms makes it a beneficial addition to treatment regimens for patients inadequately controlled by conventional therapies. However, due to potential hepatic concerns and drug interactions, careful patient selection, dosing, and monitoring are essential. Always consult with your healthcare provider to determine if seratrodast is appropriate for your condition and to tailor the treatment to your individual needs.

Disclaimer: This information is provided for educational purposes only and should not replace professional medical advice. Always consult with your healthcare provider before initiating or modifying any medication regimen.